Evaluating the Impact of Vagus Nerve Stimulation on Diabetic Peripheral Neuropathic Pain
NCT ID: NCT06292962
Last Updated: 2024-04-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
165 participants
INTERVENTIONAL
2023-10-01
2024-03-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Transcutaneous Electrical Nerve Stimulation in Diabetic Neuropathy
NCT04253860
Effect of Non-invasive Vagus Nerve Stimulation on Cognitive Functions in Diabetic Polyneuropathy Patients
NCT06048653
Acetylcholine Iontophoresis As A New Challenge With Type 2 Diabetic Peripheral Neuropathy: A Possible New Therapy
NCT06219590
Optimization of NIBS for Diabetic Neuropathy Neuropathic Pain
NCT03625752
tDCS and Pain Associated With Diabetic Neuropathy
NCT04306289
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants are randomized to receive either active non-invasive transcutaneous vagal nerve stimulation (tVNS) or inactive sham stimulation.
The study will investigate the effects of short-term, high-intensity tVNS treatment on peripheral pain.
The primary outcome is subjective patient evaluation of pain symptoms by the use of validated questionnaires.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group VTG
Group VTG will receive active non-invasive transcutaneous vagal nerve stimulation (tVNS)
non-invasive transcutaneous vagal nerve stimulation (tVNS)
The device is used stimulate the vagus nerve
Group STG
Group STG will receive Inactive sham stimulation
Sham device
Sham device that does not stimulate the vagus nerve
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
non-invasive transcutaneous vagal nerve stimulation (tVNS)
The device is used stimulate the vagus nerve
Sham device
Sham device that does not stimulate the vagus nerve
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients experiencing neuropathic pain
Exclusion Criteria
* Patients with serious complications of diabetes such as nephropathy and retinopathy
30 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Al Ain University
UNKNOWN
Saima Abass Tahammal
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Saima Abass Tahammal
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shifa Hospital
Lahore, , Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SH-34988389
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.